Apply to areas of concern, such as the under-eye, smile lines or forehead 2
Chronic kidney disease: GLP-1 receptor agonists have shown renoprotective effects in clinical trials (FLOW trial with semaglutide), and orforglipron could be evaluated for similar indications
Overall agreement 40%: A+ 20%, A 20%, A 45%, D 5%, D 10%, D+ 0%
Results vary from person to person and are enhanced with proper diet, hydration, and sun protection
In 2025, the Wegovy pill, an oral semaglutide option, was FDA approved for those who prefer an alternative to injections
Mackey is also certified in anti-aging medicine and bio-identical hormone replacement therapy